Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Clinical Experience
100%
Recombinant Human Thrombopoietin (rhTPO)
100%
Chemotherapy-induced Thrombocytopenia
100%
Growth Factors
50%
Megakaryocytes
50%
PEGylated
37%
Recombinant Human
37%
Development Factors
37%
Cancer Patients
25%
In Cancer
25%
Platelets
25%
Clinically Significant
12%
Clinical Development
12%
Chemotherapy
12%
Therapeutic Potential
12%
United States
12%
Neutralizing Antibodies
12%
Bone Marrow
12%
Phase I Trial
12%
Thrombocytopenia
12%
Peripheral Blood
12%
Platelet Count
12%
Truncated Version
12%
Clinical Trials
12%
Early Phase Clinical Trials
12%
Safety Profile
12%
Randomized Clinical Trial
12%
Severe Thrombocytopenia
12%
Clinical Setting
12%
Optimal Schedule
12%
Chemotherapy-induced
12%
Bone Marrow Progenitor Cells
12%
Platelet Transfusion
12%
Myelosuppressive Chemotherapy
12%
Circulating Platelets
12%
C-Mpl
12%
Clinical Safety
12%
Well Tolerated
12%
Dose-dependent
12%
Stimulating Activity
12%
Nursing and Health Professions
Thrombocytopenia
100%
Chemotherapy
100%
Thrombopoietin
100%
Clinical Trial
80%
Malignant Neoplasm
40%
Accident Prevention
40%
Economic and Social Development
40%
Platelet
40%
Platelet Count
20%
Growth Factor
20%
Thrombocyte Transfusion
20%
Neutralizing Antibody
20%
Pharmacology, Toxicology and Pharmaceutical Science
Thrombocytopenia
100%
Thrombopoietin
100%
Chemotherapy Regimen
100%
Clinical Trial
60%
Malignant Neoplasm
40%
Growth Factor
20%
Neutralizing Antibody
20%
Randomized Clinical Trial
20%